Cargando…

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey

BACKGROUND: In order to design studies assessing the optimal use of bone-targeted agents (BTAs) patient input is clearly desirable. METHODS: Patients who were receiving a BTA for metastatic prostate or breast cancer were surveyed at two Canadian cancer centres. Statistical analysis of respondent dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hutton, Brian, Morretto, Patricia, Emmenegger, Urban, Mazzarello, Sasha, Kuchuk, Iryna, Addison, Christina L., Crawley, Freya, Canil, Christine, Malone, Shawn, Berry, Scott, Fergusson, Dean, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723402/ https://www.ncbi.nlm.nih.gov/pubmed/26909279 http://dx.doi.org/10.1016/j.jbo.2013.05.002

Ejemplares similares

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
por: Hutton, Brian, et al.
Publicado: (2013)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Incidence and consequences of bone metastases in lung cancer patients
por: Kuchuk, Michael, et al.
Publicado: (2013)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)
por: Fernandes, Ricardo, et al.
Publicado: (2016)

Does estrogen play a role in response to adjuvant bone-targeted therapies?
por: Russell, Kent, et al.
Publicado: (2013)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

A national portfolio of bone oncology trials—The Canadian experience in 2012
por: Kuchuk, I., et al.
Publicado: (2012)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
por: Beltran-Bless, A., et al.
Publicado: (2021)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
por: Arnaout, Angel, et al.
Publicado: (2015)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

A primer of bone metastases management in breast cancer patients
por: Petrut, B., et al.
Publicado: (2008)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials
por: Poon, Michael, et al.
Publicado: (2012)

Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer
por: Simos, Demetrios, et al.
Publicado: (2014)

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer
por: Addison, C.L., et al.
Publicado: (2016)

Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses
por: Hutton, Brian, et al.
Publicado: (2015)

Role of bone-anabolic agents in the treatment of breast cancer bone metastases
por: Suvannasankha, Attaya, et al.
Publicado: (2014)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results
por: Fralick, M., et al.
Publicado: (2012)

Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
por: D’Oronzo, Stella, et al.
Publicado: (2020)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Bone metastases in thyroid cancer
por: Iñiguez-Ariza, Nicole M., et al.
Publicado: (2020)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting
por: Zhu, Xiaofu, et al.
Publicado: (2014)

Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts
por: Shupp, Alison B., et al.
Publicado: (2018)

Observations on Prostatic Cancer with Metastases in Bone
por: Charteris, Alexander A.
Publicado: (1927)

Prevention of bone metastases and management of bone health in early breast cancer
por: Gnant, Michael, et al.
Publicado: (2010)

Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!
por: Høilund-Carlsen, Poul Flemming, et al.
Publicado: (2018)

Therapeutic targets for bone metastases in breast cancer
por: Clézardin, Philippe
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9eis30saqn5ahfc67nus7rq6si